

September 21, 2016



Stellar Biotechnologies to Present at International Aquaculture Symposium

PORT HUENEME, CA -- (Marketwired) -- 09/21/16 -- **Stellar Biotechnologies, Inc.** ("**Stellar**" or "**the Company**") (NASDAQ: SBOT), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), will present at the VIII Simposio Internacional de Sanidad e Inocuidad Acuícola (VIII International Symposium on Aquaculture Health and Safety) in Ensenada, Baja California, Mexico, September 22-23, 2016.

The VIII Symposium on Aquaculture Health and Safety is a notable event bringing together a cross-disciplinary group of international representatives to review developments, trends and policy related to commercial aquaculture practices and sustainability in Mexico. The forum is attended by heads of research, government, academics, and business working together to influence and apply aquaculture health and safety standards in the region.

Frank Oakes, President and Chief Executive Officer of Stellar Biotechnologies, Inc., will speak on sustainable manufacture and biotechnology use of KLH, an important immune-stimulating molecule which is marine-sourced and used in pharmaceutical development.

"Stellar Biotechnologies is honored to join our international colleagues and to have this opportunity to discuss the company's achievements in aquaculture science for sustainable manufacture of KLH protein," said Mr. Oakes. "Ocean conservation is a hallmark of our business and we are especially committed to advancing aquaculture as a means to protect the resources of the Southern California and Baja California coastal regions."

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (NASDAQ: SBOT) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klbsite.org.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section

27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of the Company's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of the Company's joint ventures and strategic partnerships; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the U.S. Securities and Exchange Commission and the B.C. Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.

Stellar Biotechnologies Company Contact:

Mark A. McPartland

Vice President of Corporate Development and Communications

Phone: +1 (805) 488-2800 ext. 103

markmcp@stellarbiotech.com

www.stellarbiotech.com

Source: Stellar Biotechnologies, Inc.